Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13379918 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3BACE1CTSC | |
| SCHEMBL13379919 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3BACE1CTSC | |
| SCHEMBL3045916 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3BACE1CTSC | |
| SCHEMBL3036936 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3BACE1CTSC | |
| SCHEMBL3044611 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3BACE1CTSC | |
| SCHEMBL5543844 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3BACE1CTSC | |
| SCHEMBL4368684 | 0.86 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL25339415 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CTSCPOLB | |
| SCHEMBL22461896 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CTSCPOLB | |
| SCHEMBL20833040 | 0.79 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CTSCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691818-B2 | Peptidomimetic inhibitors of retroviral proteases and their use as antivirals | Universita' Degli Studi Di Treiste (IT) | 2010-04-06 | — | — | US | disclosed |
| EP-1768665-B1 | PEPTIDOMIMETIC INHIBITORS OF HIV PROTEASE | UNIV DEGLI STUDI TRIESTE (IT) | 2008-11-05 | — | — | EP | disclosed |
| US-20070207968-A1 | Peptidomimetic Inhibitors Of Retroviral Proteases And Their Use As Antivirals | UNIVERSITA' DEGLI STUDI DI TRIESTE (IT) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207968-A1 | Peptidomimetic Inhibitors Of Retroviral Proteases And Their Use As Antivirals | PREP, PEPD, DNPEP | SLC6A2 4200/4885SLC6A4 3506/4885SLC6A3 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.